Preferred Label : Amivantamab/Lazertinib Regimen;
NCIt synonyms : Lazertinib/Amivantamab; Amivantamab/Lazertinib; Amivantamab-vmjw/Lazertinib Regimen; Lazcluze/Rybrevant; Rybrevant/Lazcluze Regimen; Lazertinib/Amivantamab-vmjw;
NCIt definition : A regimen consisting of amivantamab and lazertinib that may be used in the treatment
of non-small cell lung cancer (NSCLC).;
Origin ID : C210441;
chemotherapy_regimen_has_component
- concept_is_in_subset
https://www.has-sante.fr/jcms/p_3639093/fr/rybrevant-/-lazcluze-amivantamab-/-lazertinib-cancer-bronchique-non-a-petites-cellules-cbnpc
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
antineoplastic combined chemotherapy protocols
Amivantamab/Lazertinib Regimen
amivantamab
Antineoplastic Agents, Immunological
carcinoma, non-small-cell lung
bronchial neoplasms
adult
EGFR Exon 19 Deletion Mutation
EGFR NP_005219.2:p.L858R
lazertinib
Tyrosine Kinase Inhibitors
Lazertinib Mesylate Monohydrate
Non-small cell lung cancer with mutation in epidermal growth factor receptor (disorder)
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3632479/fr/rybrevant-amivantamab-lazcluze-lazertinib-en-association-cbnpc
2025
false
false
false
France
lazertinib
amivantamab
Amivantamab/Lazertinib Regimen
evaluation of the transparency committee
lazertinib
antineoplastic combined chemotherapy protocols
carcinoma, non-small-cell lung
amivantamab
---
